Skip to content

Search

Showing results for "lung disease preterm"

Influenza vaccine effectiveness against laboratory-confirmed influenza in healthy children aged 6-59 months:

The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...

Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children A Case-Control Study

The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...

Topical 1,25-dihydroxyvitamin D3 subverts the priming ability of draining lymph node dendritic cells

The active form of vitamin D, 1,25-hydroxyvitamin D(3) [1,25(OH)(2)D(3)] is produced in skin following exposure to sunlight

Gene regulation by 1,25-dihydroxyvitamin D3 in CD4+CD25+ cells is enabled by IL-2

Vitamin D may be responsible for reducing the development and severity of autoimmune and allergic diseases. Topically applied 1,25-dihydroxyvitamin D(3) (1,25(O

RSV and influenza detections hit record low levels in 2020

Western Australia has experienced historically low levels of respiratory syncytial virus (RSV) and influenza this winter due to the public health measures implemented to prevent the spread of COVID-19.

Round one done, eight to go for the SToP Trial

Six weeks, nine community visits and 380 kids – it’s a wrap for round one of the StoP Trial!

COVID-19

Here’s what we know so far about the impact of COVID-19 on children.

Herpes simplex virus in infancy: Evaluation of national surveillance case capture

As herpes simplex virus in infancy is not a mandatory notifiable condition in Australia, completeness of ascertainment by the Australian Paediatric Surveillance Unit (APSU) has been difficult to evaluate to date. We evaluated case capture in Queensland and Western Australia using statewide laboratory and clinical data and complementary surveillance data collected via the APSU.

Invasive mould infection in children – advances made or obstacles remaining?

Invasive mould infection (IMI) is a major cause of morbidity and mortality in immunocompromised children. Outcomes for paediatric patients with IMI remain poor, due in part to the limitations of available diagnostic tools and therapeutic agents.